University of Texas Texas AM Investment Management Co. Purchases New Holdings in Royalty Pharma plc (NASDAQ:RPRX)

University of Texas Texas AM Investment Management Co. bought a new stake in Royalty Pharma plc (NASDAQ:RPRX - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 47,786 shares of the biopharmaceutical company's stock, valued at approximately $1,219,000.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Barclays PLC raised its stake in shares of Royalty Pharma by 16.3% in the 3rd quarter. Barclays PLC now owns 308,887 shares of the biopharmaceutical company's stock valued at $8,737,000 after acquiring an additional 43,339 shares in the last quarter. Assenagon Asset Management S.A. acquired a new position in Royalty Pharma during the 4th quarter worth $486,000. Ballentine Partners LLC bought a new stake in Royalty Pharma during the fourth quarter valued at about $200,000. Impact Partnership Wealth LLC acquired a new stake in shares of Royalty Pharma in the fourth quarter valued at about $467,000. Finally, Fifth Third Bancorp increased its stake in shares of Royalty Pharma by 187.1% in the fourth quarter. Fifth Third Bancorp now owns 1,530 shares of the biopharmaceutical company's stock worth $39,000 after purchasing an additional 997 shares during the period. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Wall Street Zen downgraded Royalty Pharma from a "buy" rating to a "hold" rating in a research note on Tuesday, May 20th. Morgan Stanley initiated coverage on Royalty Pharma in a report on Friday, May 16th. They set an "overweight" rating and a $51.00 price target for the company. Finally, Citigroup restated a "buy" rating on shares of Royalty Pharma in a research note on Friday, March 28th. Two analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $42.50.

Royalty Pharma Price Performance

Shares of RPRX stock traded down $0.09 during trading hours on Wednesday, hitting $32.60. The company had a trading volume of 1,051,433 shares, compared to its average volume of 3,464,590. Royalty Pharma plc has a 12 month low of $24.05 and a 12 month high of $34.32. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.44 and a current ratio of 1.44. The firm's fifty day moving average is $32.36 and its 200 day moving average is $30.28. The firm has a market capitalization of $18.79 billion, a price-to-earnings ratio of 22.51, a PEG ratio of 2.31 and a beta of 0.49.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.99 by $0.07. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. The firm had revenue of $839.00 million during the quarter, compared to analyst estimates of $724.69 million. On average, sell-side analysts predict that Royalty Pharma plc will post 4.49 EPS for the current fiscal year.

Royalty Pharma Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be given a $0.22 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $0.88 dividend on an annualized basis and a yield of 2.70%. Royalty Pharma's dividend payout ratio (DPR) is presently 47.57%.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.